alexa CMC Considerations For Biosimilar Drug Development
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

7th European Biosimilars Congress
May 15-16, 2017 Munich, Germany

Ulrike Konrad
Karl Ruprecht Universität, Germany
ScientificTracks Abstracts: J Bioanal Biomed
DOI: 10.4172/1948-593X-C1-026
Abstract
Developing a biosimilar from a CMC perspective is a scientific and risk based approach and not a list with checkboxes to be ticked off. Following the quality strategy, the biosimilarity cannot be tested in the clinical trials but must be demonstrated on the drug substance and product level. For this, there are typical road maps always starting with a quality target product profile of the originator molecules. This talk will focus on typical analytical modules on the road map also touching the comparison of degradation profiles and impurities of biosimilar and originator molecules in a side-by-side analytical situation. All that must be adapted to the company’s strategy for market, time for development, budget and partners. Typical examples will be presented combined with pitfalls that companies are facing during the development.
Biography

Ulrike Konrad has more than 10 years of experience in Biotech/Pharma with focus on protein analytics and biosimilar development to reach and demonstrate biosimilarity. She graduated in Chemistry from the University in Heidelberg, Germany and has done her Master of Business Administration. She has worked as a Project Manager in different Biotech companies and joined Protagen Protein Services in 2012. In her role, she has supported numerous biosimilar developments including the consulting for the analytical and regulatory strategy for Europe, USA, India, Korea, Brazil and Mexico.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords